Bladder Cancer Therapeutics Market

Global Bladder Cancer Therapeutics Market Size (2023 to 2028)

The size of the global bladder cancer therapeutics market is expected to grow to USD 336.8 million by 2028 from USD 264.5 million in 2023, growing at a CAGR of 4.95% during the forecast period.

Global Bladder Cancer Therapeutics Market Share Insights:

• Based on type, the transitional cell bladder had the major share in the global market in 2022.
• Based on treatment, the chemotherapy segment was the leader in the market in 2022.
• North America captured 41% of the global market share in 2022.
• The European region held a notable share of the worldwide market in 2022. 

Bladder cancer is preventable when detected in the early stage using surgery, chemotherapy, and radiation. The symptoms of bladder cancer include blood in urine, difficulty in urination, and lower back pain. According to the World Cancer Research Foundation (WCRF), countries such as Greece, Netherlands, Italy, Denmark, Spain, and Germany had the highest incidence of bladder cancer in 2020. The risk of developing bladder cancer is 1 in 28 men and 1 in 91 women. Bladder cancer treatments include urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and others. According to the American cancer society, 81,400 new cancer cases were registered in 2020. It was estimated that 62,100 were men and 19,300 were women cancer patients. In 2019, the CANADA center for drug research and development announced USD 1.2 million investment in Sitka biopharma. The development activities for clinical trials named STK-01 are used to treat bladder cancer nanotechnology. 

MARKET DRIVERS:

The growing population who have bladder cancer, innovations in drugs for treatment, and technological advances are propelling the global bladder cancer therapeutics market growth.

The incidence of bladder is growing significantly across the world. According to National Health Institute, an estimated 81180 new bladder cases and 17100 deaths are expected to happen due to bladder cancer in 2022. According to World Cancer Research Fund International, 573000 new bladder cancer cases were registered worldwide in 2020. Unhealthy habits such as smoking and having a family history of bladder cancer can result in diagnosing this cancer in a person, and it is most likely to be seen in people over 55 years. Hence, the growing aging population worldwide is anticipated to contribute to the growth of the bladder cancer therapeutics market. Furthermore, increasing government initiatives, growing awareness of bladder cancer, available treatments, and progressive health services associated with increased spending on healthcare also boost the global bladder cancer therapeutics market. Since cancer is an asymptomatic disease in the initial stage, it requires an accurate diagnosis at an early stage.

Technological advancements, new treatment options, advanced healthcare services, increasing awareness around bladder cancer therapies among people, the launch of new novel drugs, the acceptance of effective diagnostic tools, and the rise in healthcare expenditure are the factors that drive the global bladder cancer therapeutics market growth. In addition, the launch of new products, a rise in investments to conduct R&D, and increasing efforts from the market participants to strengthen their position are anticipated to promote the market’s growth rate.

MARKET RESTRAINTS:

Poor availability of various treatment options regarding various treatment options and lack of awareness among people of bladder cancer therapeutics are hindering the market growth. High costs associated with the medical devices used in bladder cancer therapeutics further hamper the market's growth rate. In addition, stringent regulations are inhibiting market growth. The lack of healthcare infrastructure and limited adoption of advanced cancer therapies in some countries worldwide are showcasing a negative impact on the growth of the global bladder cancer therapeutics market. The scarcity of skilled professionals in diagnostic labs is another major obstacle to the bladder cancer therapeutics market growth.

Impact of COVID-19 on the global bladder cancer therapeutics market:

The coronavirus disease (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) has affected many individuals and healthcare systems. The primary concern is associated with the difficulty in engaging with healthcare systems. Bladder cancer majorly occurs in the elderly population. The global economy and the market were adversely affected; the market structure has been completely changed. Countries are in an international run to expand and produce a vaccine for SARS-COV-2. Government bodies are increasing funding for vaccine development. A nationwide lockdown had been implemented due to a surge in the covid-19 cases. The concerning activities on bladder cancer therapeutics had stopped and been postponed. 

The market expects significant growth despite the negative impact during the forecast period. Several new bladder cancer cases have been registered in the recent period through which market expansion can be possible. In addition, different cancer therapies, such as immunotherapies in cancer treatment, are recharged among the people. It recently developed treatment modalities that are conventional therapeutic options in bladder cancer management. However, the market is anticipated to witness a healthy growth rate during the forecast period.

REPORT COVERAGE:

This research report on the global bladder cancer therapeutics market has been segmented and sub-segmented based on type, treatment, and region.

Bladder Cancer Therapeutics Market - By Type:

• Transitional Cell Bladder Cancer
• Non-Muscle Invasive/Superficial Bladder Cancer
• Invasive Bladder Cancer
• Squamous Cell Bladder Cancer
• Adenocarcinoma of the Bladder
• Rare Bladder Cancers

Based on the type, the transitional cell bladder segment held the largest share of the global bladder cancer therapeutics market in 2021 due to improving healthcare infrastructures in developed and developing countries.

The superficial bladder cancer segment is expected to grow at a brisk pace in the global bladder cancer therapeutics market during the forecast period, and the growth of this segment is attributed to improving healthcare infrastructures in developed and developing countries, rising awareness about the superficial bladder, and technological advancements.

Bladder Cancer Therapeutics Market - By Treatment:

• Surgery
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Intravesical Therapy

Based on the treatment type, the chemotherapy segment held the highest share due to the many chemotherapy drugs in 2021. On the other hand, the immunotherapy segment is predicted to showcase a healthy growth rate in the global bladder cancer therapeutics market. The immunotherapy segment growth is driven by the increasing prevalence of targeted diseases, the growing adoption of immunotherapy over conventional treatments, and the rising demand for monoclonal antibodies and biosimilars.

Bladder Cancer Therapeutics Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American bladder cancer therapeutics market accounted for 41.0% of the global market in 2021. In contrast, Asia-Pacific is expected to grow at the highest CAGR of 5.68% from 2022 to 2027. Therefore, North America is predicted to lead the market for bladder cancer therapeutics during the forecast period. Most of the region is attributed to increased bladder cancer incidence, innovative healthcare solutions, advanced healthcare infrastructure, and growing concern about bladder problems.

The Europe bladder cancer therapeutics market represented the second-largest global market share in 2021 and is anticipated to showcase a promising growth rate during the forecast period. This is because the number of people with bladder cancer in the European region is growing considerably. According to Cancer Research UK, an estimated 10300 bladder cancer cases were registered in the United Kingdom between 2016 to 2018, and are considered the 11^th most dangerous cancer in the UK.

The bladder cancer therapeutics market in Asia-Pacific is expected to experience substantial growth. This increase is mainly due to the growing awareness of bladder diseases and innovative diagnostic and treatment options. As a result, the leading market players believe that Asian countries are lucrative markets for bladder cancer and make significant investments, leading to market growth. There is a considerable increase in the number of people diagnosed with bladder cancer with each year passing in the Asia-Pacific region. India had 18921 bladder cancer cases and 10231 mortalities in 2018.

The Latin American bladder cancer therapeutics market is expected to rise at a CAGR of 5.18% from 2022 to 2027. The awareness of bladder cancer among the countries of Latin America has increased in the recent past, favoring market growth. For example, according to World Health Organization, an estimated 9127 bladder cancer cases were found in Brazil in 2018. In addition, the growing adoption of technological advancements and the rising focus of market participants to develop new drugs are expected to accelerate market growth in this region shortly.

The bladder cancer therapeutics market in the Middle East and Africa is forecasted to value USD 30.55 million by 2027. Bladder cancer is one of the most common cancers in developing countries such as the UAE. The death rate from bladder cancer was highest in Egypt in 2020. Due to the presence of underdeveloped countries in Africa and the lack of proper healthcare infrastructure, the bladder cancer therapeutics market in Africa is struggling to see expansion. On the contrary, with the growing investments from the market participants, this region is expected to see slight growth during the forecast period.

KEY MARKET PLAYERS:

Companies leading the Global Bladder Cancer Therapeutics Market profiled in the report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland) and Celgene Corporation (U.S.)

RECENT MARKET DEVELOPMENTS:

• In January 2020, Pfizer and Merck KGaA jointly announced that U.S. FDA approved PD-L1 inhibitor Bavencio. Also, they stated that this is evaluating positive data from the interim analysis of a phase-III study and soon going to show better results in patients suffering from advanced/metastatic urothelial carcinoma, a form of bladder cancer.